Old Web
English
Sign In
Acemap
>
Paper
>
First-Line Pembrolizumab Therapy of Non-Small Cell Lung Cancer: Baseline Metabolic Biomarkers Predict Outcomes
First-Line Pembrolizumab Therapy of Non-Small Cell Lung Cancer: Baseline Metabolic Biomarkers Predict Outcomes
2021
David Lang
Linda Ritzberger
Vanessa Rambousek
Andreas Horner
Romana Wass
Kaveh Akbari
Bernhard Kaiser
Jürgen Kronbichler
Bernd Lamprecht
Michael Gabriel
Keywords:
Pembrolizumab
first line
Immunotherapy
Oncology
Medicine
Internal medicine
non small cell
Lung cancer
metabolic biomarkers
PET-CT
Standardized uptake value
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]